Zoonoses and gold mining: A cross-sectional study to assess yellow fever immunization, Q fever, leptospirosis and leishmaniasis among the population working on illegal mining camps in French Guiana

Maylis Douine1,2,3*, Timothée Bonifay1, Yann Lambert1, Louise Mutricy1, Muriel Suzanne Galindo1, Audrey Godin1, Pascale Bourhy5, Mathieu Picardeau4, Mona Saout2, Magalie Demar1,6, Alice Sanna1, Emilie Mosnier6, Romain Blaizot2,7, Pierre Couppie2,7, Mathieu Nacher1,2,3, Antoine Adenis1,2,3, Martha Suarez-Mutis8, Stephen Vreden9, Loïc Epelboin1,2,10, Roxane Schaub1

1 Centre d’Investigation Clinique Antilles-Guyane (Inserm 1424), Centre Hospitalier de Cayenne, Cayenne, French Guiana, 2 TBIP, Université de la Guyane, Cayenne, French Guiana, 3 Centre de Ressources Biologiques Amazonie, Cayenne, French Guiana, 4 National Reference Center for Leptospirosis, Biology of Spirochetes unit, Institut Pasteur, Paris, France, 5 University Laboratory of Mycology-Parasitology, Centre Hospitalier de Cayenne, Cayenne, French Guiana, 6 Delocalized Health Centers, Centre Hospitalier de Cayenne, Cayenne, French Guiana, 7 Department of Dermatology, Centre Hospitalier de Cayenne, Cayenne, French Guiana, 8 Laboratory of Parasitic Diseases, Institute Oswaldo Cruz/Fiocruz, Rio de Janeiro, Brazil, 9 Foundation for Scientific Research Suriname, Paramaribo, Suriname, 10 Infectious and Tropical Diseases Unit, Centre Hospitalier de Cayenne, Cayenne, French Guiana

* mdouine@yahoo.fr

Abstract

Background

Most emerging pathogens are zoonoses and have a wildlife origin. Anthropization and disruption of ecosystems favor the crossing of inter-species barriers. We hypothesize that the marginalized population of undocumented goldminers in the Amazon is at risk of acquiring zoonoses.

Method

A multicentric cross-sectional study included consenting gold-mining adult workers in 2019. A clinical examination recorded dermatological signs of leishmaniosis and past history of yellow fever vaccination. Biological tests were performed for yellow fever, Q fever and leptospirosis serologies. Additional blood samples from a previous study in 2015 were also tested for leptospirosis.

Results

In 2019, 380 individuals were included in the study, along with 407 samples from the 2015 biological collection. The seroprevalence of leptospirosis was 31.0% [95%CI = 26.4–35.5] in 2015 and 28.1% [23.5–32.7] in 2019. The seroprevalence of Q fever was 2.9% [1.2–4.6].
The majority of participants reported being vaccinated against yellow fever (93.6%) and 97.9% had seroneutralizing antibodies. The prevalence of suspected active mucocutaneous leishmaniasis was 2.4% [0.8–3.9].

Discussion

These unique data shed new light on the transmission cycles of zoonoses still poorly understood in the region. They support the existence of a wild cycle of leptospirosis but not of Q fever. Leishmaniasis prevalence was high because of life conditions and tree felling. High yellow fever vaccine coverage was reassuring in this endemic area. In the era of global health, special attention must be paid to these vulnerable populations in direct contact with the tropical ecosystem and away from the health care system.

Author summary

Many pathogens are zoonotic in origin and human transmission can occur via vector, direct contact, inhalation, absorption, among other routes enabling human-reservoir interaction. In Amazonia, the cycle of these pathogens (the reservoir, the mode of transmission . . .) is not always well known. It is important to better understand these cycles in order to evaluate and anticipate the potential risk for human health, both on an individual and collective scale (risk of epidemic). In French Guiana, a French territory located in the Amazon, undocumented gold miners represent several thousand people mainly from Brazil who work in very remote areas in the middle of the rainforest. Documenting several zoonotic diseases among this population living in the middle of biodiversity is very valuable to better understand these cycles but also to assess the impact for their own health and to identify risks for public health. This article provides new data for four zoonoses: Q-fever, leptospirosis, leishmaniasis and yellow fever in this population and discusses the contributions to the understanding of cycles and public health issues.

Introduction

Since 1940, the emergence of pathogens has significantly increased worldwide [1,2]. Among these pathogens, 60% are from zoonotic origin, mainly from wildlife (72%), and this proportion is still increasing (2). Vector-borne diseases represent 22.8% of the emerging infectious diseases (EID). There are many reasons for these emergences, such as environmental changes that favor the development of vectors and reservoirs, human behavior especially deforestation of tropical forests, the movement of people, animals and their products around the world, the densification of populations or the massive displacements [3]. The anthropization and disruption of ecosystems favor the crossing of inter-species barriers, especially in areas of high biodiversity such as the Amazon basin, where French Guiana is located. In this French overseas territory, the life cycles of multi-host diseases appear to be even more complex than in other Central and South American settings [4]. This suggests that the greater promiscuity between wildlife and humans due to demographic and economic pressures may provide new contexts for the movement and spread of microbes and their hosts [4].

Among the known risk factors associated with EID, several are prominent in the gold mining activity, such as deforestation, which creates breeding areas for vectors, hunting, close
contact with wildlife, or poor sanitary conditions [4,5]. Deforestation also causes contact between humans and vectors usually living in the canopy, and ending up on the ground following the felling of trees. In addition, the remoteness of health facilities leads to care seeking delays and thus might increase potential human-to-human transmission and significant morbidity [6]. For example, malaria strongly affects the gold mining population due to vector exposure (Anopheles) and inadequate or delayed health care seeking behavior, thus increasing the human reservoir of parasites [7,8]. In French Guiana, the estimated 12,000 gold miners working illegally on hundreds of gold mines in the heart of the Amazon forest are mainly Brazilian nationals and frequently travel through the Guiana Shield and Brazil [9]. In addition to the possibility of pathogen emergence and morbidity in this population, this high mobility also poses the risk of pathogen dissemination.

It is therefore very important to assess zoonoses among this population in order to better understand pathogen cycles and to anticipate public health issues. The present study aims to evaluate the epidemiological situation of four zoonoses in the French Guianese context: yellow fever, Q fever, leptospirosis and leishmaniasis.

Material and methods

Ethics statement

The protocol was approved by the National Ethics Board of Suriname (CMWO (Commissie voor Mensgebonden Wetenschappelijk Onderzoek), Opinion Number VG 25–17). The authorization of importation of human biological samples was obtained and the biological collection declared to the French Ministry of Education and Research (DC-2014-2160 and DC-2021-4649). The database was anonymized and registered according to the General Data Protection Regulation (GDPR).

A written consent form was collected after information in the participant’s language on the primary objective of the study related to malaria and secondary objectives related to zoonoses with medical examination (leading to referral to care in case of suspected health problem) and the use of the biological samples for further epidemiological investigations (without rendering personal results).

Type of study

This study is based on a cross-sectional study conducted in 2019 to describe malaria epidemiology among illegal gold miners working in French Guiana. The study design is fully described elsewhere [7,8].

Four zoonoses were selected as secondary objectives because of their interest for public health in the French Guianese context (Table 1).

Population study

Participants were enrolled by snow-ball sampling in staging areas, places where gold miners go to sell their gold, buy supplies, rest, or visit family (Fig 1). These places are located along the Maroni River at the border with Suriname. Inclusions were conducted by a trio formed by a health mediator to facilitate communication with the target population, a nurse and a physician.

Inclusion criteria were being over 18 years of age, working at a gold mining site in French Guiana, having left the mine for less than 7 days and agreeing to participate in the study.
## Table 1. Diseases studied with their ecology, epidemiology, public health issue in the Amazon and assessment method in this study.

| Pathogens | Yellow Fever | Q Fever | Leptospirosis | Leishmaniasis |
|-----------|--------------|---------|---------------|---------------|
|           | Yellow fever virus | Coxiella burnetii | Leptospira sp. | Leishmania guyanensis |
|           |               |         |               | Leishmania braziliensis |
|           |               |         |               | Others |
| Pathogen cycle in the Amazon | Non-human primates | Unclear | Rodents and many mammals described as carriers of Leptospira sp. in South America [10,11] | • L. guyanensis: two-toed sloth (Choloepus didactylus) |
|           |               |         |               | • L. braziliensis: rodents, Didelphidae . . . |
| Transmission mode | Vector-borne through Haemagogus sp. and Aedes sp. | Probable inhalation of contaminated aerosols | Contact of mucous membranes or injured skin with water and soil contaminated with urine of reservoir animals | Vector-borne through Lutzomyia sp |
| Public health significance of assessment in the gold miners population | Risk of epidemic in French Guiana due to the proximity of gold miners and non-human primates in the forest and the presence of the vectors if low vaccination coverage | Better understand the mode of transmission and the reservoir by looking at whether people living in constant contact with biodiversity are more affected | • Evaluation of the morbidity linked to leptospirosis among this exposed population | • Pathology complained as a major problem by the concerned population [6] |
|           |               |         |               | • Evaluation of the risk of misdiagnosis of febrile illnesses in this highly malaria-exposed population |
|           |               |         |               | • Increased proportion of L. braziliensis which poses therapeutic challenges |
|           |               |         |               | • Rumors of intense circulation of black market anti-leishmanial drugs known for potentially severe adverse effects |
| Outcome | • vaccination coverage (declared) | Seroprevalence of Q-fever | • Seroprevalence of leptospirosis | • prevalence of active leishmaniasis lesion |
|           |               |         |               | • Identification of the different serovars |
|           |               |         |               | • proportion of different Leishmaniasis species |
| Evaluation criteria | • questionnaire about previous yellow fever immunization | • questionnaire about use of antileishmaniosis treatment during the last year | | • use of anti-leishmaniasis drugs during the previous year |
| medical exam | | | | • medical examination: active lesions of leishmaniasis (specific training of the investigating physician in the dermatology department of the Cayenne hospital) |
| lab analyses | • Seroneutralizing antibody test | • Phase I and II IgG using Enzyme-Linked Immunosorbent Assay (ELISA) | • Microscopic Agglutination Test (MAT) | • Swab of the bottom of the lesion in case of active lesion for PCR |
|           |               |         |               | • For phase I antibodies, the sample was considered positive when the serum OD was >10% above the OD cut-off value. For phase II, antibody activities in IU/mL were calculated following manufacturer’s guidelines using a standard curve which was supplied in the kit. |
|           |               |         |               | • A positive case was defined as having a positive MAT with a titer \( t > = 1/50 \) (Goris and Hartiskeerl 2014) |
|           |               |         |               | • A seropositive case was defined as having IgG Phase I positive and/or IgG Phase II positive |
|           |               |         |               | • Description of serovars with titer \( t > = 1/800 \) due to numerous cross-reactions |

(Continued)
**Table 1.** (Continued)

| Study population (Samples collected) | Yellow Fever | Q Fever | Leptospirosis | Leishmaniasis |
|-------------------------------------|--------------|---------|---------------|---------------|
| • 380 persons included on the Maroni river in 2019 (376 samples analyzed *) | • 380 persons included on the Maroni river in 2019 (380 samples analyzed) | • 421 persons included on the Maroni river in 2015 (412 samples analyzed) | • 380 persons included on the Maroni river in 2019 (378 samples analyzed *) |

* some of the samples were not full enough to make the aliquots needed for these analyses, resulting in a different number of samples than the number of people included

Fig 1. Map of inclusion sites at the Suriname-French Guiana border (map background from dmap https://d-maps.com/pays.php?num_pay=5267&lang=fr).

https://doi.org/10.1371/journal.pntd.0010326.g001
Collected data and evaluation criteria

The cross-sectional survey took place from October to December 2019 (2019 study). Samples from a previous study on similar population in 2015 were added for measuring leptospirosis seroprevalence and its evolution over 4 years. The data presented here are primarily from the 2019-study.

A questionnaire collected sociodemographic information as well as previous yellow fever vaccination (both self-reported and verified by vaccination record if available, number of injections) and use of antileishmanial treatment in the last year and how they obtained it (health facility or self-medication). Medical examination looked for the presence of suspected active mucocutaneous leishmaniasis lesions.

A blood sample was taken at the time of inclusion, centrifuged in the evening, stored at 4˚C. The sera were stored at the Biobank Amazone at -80˚C, located in the Cayenne Hospital. The samples were sent afterwards to the different laboratories for further investigation (S1 Circuit: Circuit and pre-analytical conditioning of blood samples). Diagnostic methods are described in Table 1.

Statistical analyses

An initial analysis described the study population (median with interquartile range or mean with standard deviation according to the variable’s distribution for quantitative variables, frequencies and proportion for qualitative variables) and the prevalence of each zoonosis with 95% confidence intervals. Bivariate analyses assessed the association with potential risk factors, using appropriate tests (chi2 or student’s T tests). Variables with a p-value < 0.20 in bivariate analyses were included in a multivariate logistical regression model to assess factors independently associated with leptospirosis. All statistical analyses were performed using Stata 13 (College Station, Texas).

Results and discussion

Study population

The characteristics of the 380 individuals included in the 2019 cross-sectional study are described in Table 2. The population included in the 2015 study (N = 421), from which the additional samples tested for leptospirosis came, was comparable and previously described in Douine et al, 2017 [6].

Yellow fever

Among the 378 persons who answered the question (two did not know), 93.6% 95%CI [91.2;96.1] reported having received at least one YF vaccine injection. They had received a median of two doses [IQR = 1–2]. YF neutralizing antibodies were found in 368 out of 376 samples analyzed (97.9% 95%CI [96.4;99.3]). Almost all (343/350, 98.0%) of the participants who reported having been vaccinated had indeed protective antibodies; 95.8% (23/24) of those who said not having been vaccinated had, however, protective antibodies. Among the eight persons without YF antibodies, seven declared they were vaccinated. These non-protected persons were young (median = 34.5 YO [28–40]), sex-ratio 1:1, and six with secondary education level.

Despite the existence of an effective vaccine since 1937, yellow fever is responsible for several hundred of cases annually in South America [12,13]. The sylvatic reservoir puts the population living in or near the forest most at risk, as was reported during the large outbreak in Brazil in 2016–2019 [14]. Human-to-human transmission can occur in urban areas due to
vector transmission involving *Aedes* sp. The high vaccination coverage of YF in the gold miners’ population (97.9%), above the WHO recommendation of 80%, reflects the effective immunization program in Brazil where the vaccine is free of charge and mandatory for children and

Table 2. Characteristic of the study population of 380 clandestine gold miners working in French Guiana, 2019.

|                              | n (%)           |
|------------------------------|-----------------|
| **Socio-demographic data**   |                 |
| **Age**                      |                 |
| Median age [IQR]             | 39 [31–48]      |
| <= 29 yo                     | 80 (21.1)       |
| 30–44 yo                     | 168 (44.2)      |
| > = 45 yo                    | 132 (34.7)      |
| **Sex**                      |                 |
| Women                        | 102 (26.8)      |
| Men                          | 278 (73.2)      |
| **Education level**          |                 |
| None or primary              | 130 (34.3)      |
| Secondary                    | 239 (63.1)      |
| Superior                     | 10 (2.6)        |
| **Country of birth**         |                 |
| Brazil                       | 363 (95.5)      |
| Other than Brazil            | 17 (4.5)        |
| **Gold mining activity**     |                 |
| **Time in gold mining activity** |              |
| <= 5 years                   | 118 (31.1)      |
| 6–10 years                   | 87 (22.9)       |
| 11–15 years                  | 55 (14.6)       |
| > 15 years                   | 119 (31.4)      |
| **Time spent in the last mining site** |            |
| <= 6 months                  | 231 (61.8)      |
| >6months                     | 143 (38.2)      |
| **Travel time to the actual gold mining site** |          |
| <= 2 hours                   | 29 (7.8)        |
| 2 hours to half day          | 117 (31.4)      |
| 1 day                        | 92 (24.6)       |
| > 1 day                      | 98 (26.3)       |
| Do not know                  | 37 (9.9)        |
| **Main activity on the mine**|                 |
| Gold miner                   | 230 (60.4)      |
| Machine operator             | 6 (1.6)         |
| Sex worker                   | 1 (0.3)         |
| Carrier                      | 16 (4.2)        |
| Bar owner                    | 4 (1.1)         |
| Store owner                  | 3 (0.8)         |
| Housekeeper/cook             | 54 (14.2)       |
| Mobile salesman              | 52 (13.7)       |
| Unemployed                   | 3 (0.8)         |
| Transporter                  | 1 (0.3)         |
| Other                        | 7 (1.8)         |
| Do not know                  | 3 (0.8)         |
| **Type of activity**         |                 |
| Non-mobile activity*         | 305 (80.2)      |
| Mobile activity**            | 72 (19.0)       |
| Do not know                  | 3 (0.8)         |
| **Number of stays outside from mining site > 3 days during the last year** | 3 [2–6]

* main activity on the mine itself as gold miner, cook...  
** main activity involving great mobility as a transporter, dugout driver...  

https://doi.org/10.1371/journal.pntd.0010326.t002
recommended in inhabitants of municipalities of the Amazon region, where most miners come from. In the local population of FG, YF vaccine is mandatory, free of charge and readily accessible. Vaccination coverage is estimated at 95.9% 95%CI [95.5;96.3] in primary and secondary school children and 95.0% 95%CI[93.4;96.2] in the general population, but heterogeneous with lower coverage in the vulnerable population (Maroni river region, clandestine immigrants, precarious people . . .) [15]. The study population appears to be familiar with the YF vaccine as evidenced by the good correlation between reported prior vaccination and the presence of neutralizing antibodies. Although YF vaccination coverage is reassuring in the gold miners’ population, caution is warranted. Indeed, four cases of YF were reported in FG over the past five years, all in unvaccinated people (except one who received one dose in childhood), and all died. Two of them were likely related to gold mining [4,16] (and pers. Com). Physicians should remain vigilant and think of this diagnosis on suggestive symptoms and reported dead monkeys or human cases require a rapid investigation and health response. This surveillance is all the more important as the vaccination schedule has been changed since 2014 from one dose every 10 years to a lifetime dose by the WHO with uncertainties about the persistence of immunity over time [17].

**Q fever**

Among the 380 samples, 11 were positive for Q fever (2.9% 95%CI [1.2;4.6]): 6 were positive for both IgG phase I and phase II, 3 for only one IgG and 2 borderline. Among the positive, there were 10 men and one woman, the median age was 45 QIR [34;54] years. Nine were gold miners working directly on the mines (alluvionnary or pits), and they came from six different mining basins widely scattered.

Q fever in French Guiana has a particular epidemiology: the incidence rate is the highest described in the world [18], and its clinical presentation is specific, with more than 25% of community-acquired pneumonia related to *Coxiella burnetii* in French Guiana [19]. If we add to this the potential chronic phase with—among others—cardiovascular disorders, this disease turns into a public health problem in FG. The reservoir is still unknown, despite the incrimination of a species of sloth (*Bradypus tridactylus*) and capybara (*Hydrochoerus hydrochaeris*) from which seropositive samples were found [20]. The seroprevalence of Q-fever among the study population (2.9%) living almost exclusively in the rain forest is lower than that of the general population of FG, estimated at 9.6% in the EPIARBO study (Flamand, C. pers. Com) and up to 20% in the Cayenne urban area and in the agricultural commune of Cacao. In Brazil, the country of origin for most of the gold miners, few data are available showing a seroprevalence of 3.2% among people living with HIV and of 9.3% among intravenous drugs users, which are not comparable to our study population [21,22]. The low seroprevalence in our study does not suggest the existence of a sylvatic reservoir and could be related to reduced presence of livestock in their environment compared to that of the general French Guianese population. Q fever does not seem to constitute a public health issue in this population. Further studies to better understand the reservoir are underway and will shed light on which preventive measures are needed for the most at-risk populations.

**Leptospirosis**

The seroprevalence of leptospirosis was measured at 31.0% 95%CI [26.4;35.5] (126/407) in 2015 (5 non-analyzable samples) and 28.1% 95%CI [23.5;32.7] (104/370) in 2019 (8 non-analyzable samples). The antibodies titers were quite low with only six patients presenting titers > = 1/800. Among the latter, serovar analysis shows 2/6 *L. interrogans sv Icterohaemorrhagiae* (Table 3).
The seroprevalence was higher in men than in women. Although not significant, it appears that leptospirosis affects mainly men working directly in the mines, especially alluvial mines (Table 4). In univariate analysis, the northwestern part of FG seems to be more affected, but the high mobility of the gold miners prevents conclusions from being drawn.

The seroprevalence of leptospirosis is very high among this population of gold miners (31.0% and 28.1%), when compared to groups with known occupational risk like slaughterhouse workers in New-Zealand (seroprevalence = 10–31% [23]), sewer workers in India (16.6% [24]), or urban cleaners in Paraguay (8.6% (IgG) [25]). In French Guiana, leptospirosis has long been considered as anecdotal but the incidence increased since 2012 with the availability of better diagnosis tools like PCR and IgM serology, until reaching one of the highest in the world [26,27]. A high proportion (25%) of 48 leptospirosis infections diagnosed between 2007 and 2014 were related to gold mining activities [28]. In Brazil, incidence data show that the states of Acre and Amapa have the highest incidences (30.7/100,000 inhab. and 11.7/100,000 inhab.) [29]. The majority of the gold miners come from the States of Maranhão and Pará were the incidences are of 0.4 and 1.8/100,000 inhab. respectively. The duration of antibodies against leptospirosis in the blood persists from a few months for IgM to several years for IgG [30]. Therefore, it is indeed difficult to conclude where the subjects of the study were exposed. However, in South America, many mammals have been identified as Leptospira reservoirs [10,11]. The Leptospira has been shown to be adapted to tropical climates and aquatic environment such as that of the gold miners [31]. It is therefore possible that there is wild cycle of leptospirosis in Amazonian ecosystems. The symptoms of leptospirosis and malaria—which is highly prevalent in the gold miner population—can be similar, especially at the onset of the disease, thus acute leptospirosis might be underdiagnosed in these population who used to use self-medication with antimalarial antibiotics bought on the black market [32,33]. But using the wrong medication can worsen the health condition and even lead to death, although doxycycline maybe useful in both infections. An innovative health intervention implemented

| Date | Serovar tested | Titer value | Patient | Gold mining activity* | Medical context at inclusion |
|------|----------------|-------------|---------|-----------------------|-----------------------------|
| 2015 | *L. borgpetersenii sv Castellonis* | 1/800 | 36-year-old man | gold miner in Eau-Claire region, working for 1 year in gold mining | No fever or other clinical signs, malaria RDT and PCR negative |
|      | *L. kirschneri sv Grippotyphosa* | 1/800 | 31-year-old man | gold miner in Mana region, working for 2 years in gold mining | No fever or other clinical signs, malaria RDT and PCR negative |
|      | *L. interrogans sv Icterohaemorrhagiae* | 1/800 | 28-year-old man | dugout driver in Sophia region, working for 6 months in gold mining | Apyretic, asymptomatic, but RDT positive for *P. falciparum* confirmed in PCR |
|      | *L. interrogans sv Icterohaemorrhagiae* | 1/800 | 27-year-old man | gold miner in Mana region, working for 10 years in gold mining | No fever or other clinical signs, malaria RDT and PCR negative |
|      | *L. noguchi sv Panama* | 1/800 | 31-year-old man | gold miner in Eau-Claire region, working for 3 years in gold mining | Presented fever, no other symptoms recorded, positive RDT for *P. vivax* without PCR confirmation |
| 2019 | *L. kirschneri sv Grippotyphosa* | 1/800 | 29-year-old man | carrier in Eau-Claire region, working for 10 years in gold mining | Declared having had fever and headache 7 days before, self-medicating with Arteether-Lumefantrine (4 tablets on three occasions), no longer had headache or fever at the time of inclusion but had digestive disorders. Negative RDT and PCR for malaria, was referred to the health center for further investigations (did not go) |

* gold miner means person who worked directly on the mine and not for support (logistic, transport, mechanic...)
in the region (Malakit) aims to train gold miners to self-diagnose and self-treat malaria in case of symptoms [8]. The training provided in by Malakit should emphasize differential diagnoses and therefore the importance of having an accurate diagnosis before self-medicating.

Mucocutaneous leishmaniasis

Among the 380 persons included in the study, nine had typical active cutaneous leishmaniasis lesions, so 2.4% [95%CI [0.8;3.9]]. The M/F sex ratio was 3.5 (7/2), median age of 41 IQR [36;53] years. They were all Brazilians and they all came from mining camps located in the southwestern part of FG (municipality of Maripasoula) except one from a northwestern mine. Four participants had only one lesion, four had two, and one had four. Five were nodules, three ulcerations (Fig 2) and one non-specified.

Table 4. Factors associated with positive leptospirosis serology among the population of illegal gold miners included in the 2015 and 2019 studies (univariate and multivariate analysis).

| Socio-demographic data | 2015 N = 407 | 2019 N = 370 |
|------------------------|--------------|--------------|
| **Age**                |              |              |
| <= 29 yo               | 24 (27.3) / 0.300 | 24 (31.2) / 0.770 |
| 30–44 yo               | 61 (29.5) 1.1 [0.6–1.9] | 44 (26.7) 0.8 [0.4–1.5] |
| > 45 yo                | 41 (36.6) 1.5 [0.8–2.8] | 36 (28.1) 0.9 [4.6–1.6] |
| **Sex**                |              |              |
| Women                  | 24 (20.2) / 0.002 | 13 (13.0) / <0.001 |
| Men                    | 102 (35.4) 2.2 [1.3–3.6] | 91 (33.7) 3.4 [1.8–6.4] |
| **Education level**    |              |              |
| None or primary        | 66 (33.7) / 0.254 | 38 (30.2) / 0.545 |
| Secondary or superior  | 60 (28.4) 0.8 [0.5–1.2] | 66 (27.2) 0.9 [0.5–1.4] |
| **Country of birth**   |              |              |
| Other than Brazil      | 6 (24.0) / 0.427 | 1 (5.9) / 0.017 |
| Brazil                 | 120 (31.4) 1.5 [0.6–3.7] | 103 (29.2) 6.6 [0.9–50.4] |
| **Gold mining activity** |          |              |
| Time in gold mining activity |    |              |
| <= 10 years            | 67 (27.9) / 0.113 | 54 (27.0) / 0.671 |
| >10 years              | 59 (35.3) 1.0 [1.0–1.0] | 49 (29.0) 1.0 [1.0–1.0] |
| Time spent in the last mining site |      |              |
| <= 6 months            | 61 (29.8) / 0.679 | 53 (23.5) / 0.014 |
| > 6 months             | 63 (31.7) 1.0 [1.0–1.0] | 49 (35.5) 1.0 [1.0–1.1] |
| Travel time to the actual gold mining site |     |              |
| <= 1 day               | 38 (27.7) / 0.373 | 44 (30.8) / 0.411 |
| > 1 day                | 78 (32.1) 1.2 [0.8–2.0] | 49 (26.6) 0.8 [0.5–1.3] |
| Type of activity       |              |              |
| Other than gold miners | 55 (26.7) / 0.159 | 28 (18.9) / 0.001 |
| Gold miner             | 71 (35.3) 1.5 [1.0–2.3] | 76 (34.2) 2.2 [1.4–3.7] |
| Type of gold mine      |              |              |
| Pits                   | 5 (15.2) / 0.055 22 (31.4) / 0.511 |
| Alluvionary            | 59 (30.0) 2.4 [0.9–6.5] | 67 (27.7) 0.8 [0.5–1.5] |
| Both                   | 56 (35.2) 3.0 [1.1–8.3] | 9 (21.4) 0.6 [0.2–1.5] |
| Pace of work           |              |              |
| Day                    | 103 (32.4) / 0.178 | 76 (27.7) / 0.638 |
| Night or both          | 22 (25.0) 0.7 [0.4–1.2] | 27 (30.3) 1.1 [0.7–1.9] |
| Place of work          |              |              |
| North-West             | 40 (38.8) / 0.156 | 45 (32.1) / 0.493 |
| South-West             | 75 (29.0) 0.6 [0.4–1.0] | 55 (26.3) 0.8 [0.5–1.2] |
| South-East             | 3 (17.6) 0.3 [0.1–1.2] | 1 (33.3) 1.1 [0.1–11.9] |
| North-East             | 1 (50.0) 1.6 [0.9–25.9] | 0 (0) / |
| Number of mines worked in during the last 3 years |     |              |
| <= 3                   | 75 (29.8) / 0.506 | 66 (24.9) / 0.032 |
| >3                     | 51 (32.9) 1.0 [1.0–1.0] | 38 (36.2) 1.0 [1.0–1.0] |

* Odds-Ratio
** Adjusted Odds-Ratio after logistical regression
Among the three samples of the ulcerated lesions for PCR, one was negative, one was positive for *L. guyanensis*, and one was positive without enough amplification to identify the infecting species. Among these nine persons with active leishmaniosis lesions, five reported to have used a pentamidine injection at least once (up to four times) during the previous year: three

Fig 2. Three cutaneous leishmaniasis lesions on a gold miner included in the 2019 study.

https://doi.org/10.1371/journal.pntd.0010326.g002
got pentamidine on the black market, one went to a health center, one first went to a health center and then bought a second dose on the black market. One person self-medicated with the application of sugar with copaiba oil (*Copaifera officinalis*). Among the 362 persons without active leishmaniasis who answered the question, 17 declared having used anti-leishmanial treatment during the previous year (Table 5). The average price for under-the-counter pentamidine was 8 grams of gold for one injection—about 200 USD on gold mines.

The prevalence seemed low compared with the 8.3% 95%CI[5.8;11.4] in 2015 along the Maroni river or 4.5% 95%CI[1.4;7.6] and 7.8 95%CI[2.8;12.7] on the Oyapock River in 2018 and 2019 respectively among the same population [6](pers. Com). The study was implemented during the dry season (October to December) in a particularly dry year (2019) which can underestimate the prevalence. However, this remains much higher than in the general French Guianese population (prevalence of 0.1% (pers. Com)) or than in Amerindian population (9/639 = 1,4% [34]). Leishmaniasis is considered one of the main health problems of gold miners, who represent a high proportion of newly diagnosed cases at the hospital in Cayenne [6,35,36]. Our study raised the issue of frequent use of black market medicine with potentially serious side effects (hematological, metabolic and nervous system disorders. . .). Another issue that needs to be monitored is the increased proportion of *L. braziliensis* compared to *L. guyanensis* since the 2000s, especially near gold mining areas [37]. This may be related to a different ecosystem for this pathogen whose reservoir would not be the two-toed sloth like *L. guyanensis*, or with the advent of PCR which allows diagnostic improvements. Its morbidity is higher with mucocutaneous lesions requiring a five-day treatment with IV liposomal amphotericin B or three weeks of hospital treatment with meglumine antimoniate which is much more expensive.

Table 5. Use of anti-leishmanial treatment in the previous year among gold miners included in the 2019 study along the Maroni border.

| Use of antileishmanial treatment during the previous year | Active lesion of leishmaniasis | No active lesion of leishmaniasis |
|----------------------------------------------------------|---------------------------------|----------------------------------|
| yes                                                      | 5 (55.6)                        | 17 (4.6)                         |
| no                                                       | 4 (44.4)                        | 345 (93.0)                       |
| missing data                                             | 0 (0)                           | 9 (2.4)                          |

| Drug used                                               | Active lesion of leishmaniasis | No active lesion of leishmaniasis |
|---------------------------------------------------------|---------------------------------|----------------------------------|
| meglumine antimoniate                                    | 3 (60.0)                       | 8 (47.1)                         |
| pentamidine                                             | 1 (20.0)                       | 6 (35.3)                         |

| Place were the drug was obtained                         | Active lesion of leishmaniasis | No active lesion of leishmaniasis |
|---------------------------------------------------------|---------------------------------|----------------------------------|
| mining site                                             | 3 (60.0)                       | 8 (47.1)                         |
| health care facility                                    | 1 (20.0)                       | 6 (35.3)                         |
| both                                                    | 1 (20.0)                       | 2 (11.7)                         |
| do not know                                             | 0 (0)                           | 1 (5.9)                          |

| Number of injections during the previous year            | 1 | 2 | 3 |
|---------------------------------------------------------|---|---|---|
| 1                                                       | 2 |   |   |
| 2                                                       | 4 |   |   |
| 3                                                       | 3 |   |   |
| 4                                                       | 3 |   |   |
| 5                                                       | 1 |   |   |
| 6                                                       | 1 |   |   |
| not specified                                           | 2 |   |   |

https://doi.org/10.1371/journal.pntd.0010326.t005
Limitations

This study is the first to assess these neglected zoonotic diseases in a hard-to-reach population that is particularly at risk due to its close contact with biodiversity, poor sanitary conditions and remoteness from health facilities. However, some limitations must be taken into account when interpreting the results. The persistence of antibodies over time does not allow for a clear conclusion on the location of infection of the study subjects. The data presented concern participants included along the Maroni River and therefore do not represent the entire population of gold miners in FG. The sensitivity and specificity of the biological tests used as well as the subjectivity of the clinical examination may have led to classification bias. Seasonal variations and outbreaks may not be captured by the cross-sectional design based on seroprevalence while the incidence may vary over time. Finally, as the study was initially designed to study malaria, some outcomes have a large margin of error due to small sample size. Nevertheless, this is the first study to target this sentinel population for emerging diseases and seroprevalences allowed to get a great view of the year-round epidemiological situation.

Conclusion

While the results are reassuring regarding the risk of a yellow fever or Q fever epidemic, the high seroprevalence of leptospirosis and prevalence of clinical leishmaniasis in this vulnerable and remote population are very concerning. Although the place of contamination cannot be known, this raises the possibility of an increased risk of some anthro-po-zoonotic and vector-borne infections in the context of the small scale gold-mining in the Amazon forest. It is therefore important to carefully monitor the health status of this specific population. Other pathogens should be evaluated such as *Toxoplasma gondii*, *Trypanosoma cruzi*, or digestive parasites. In order to be able to identify emerging pathogens, it could be interesting to put in place exploratory studies such as metagenomics. For example, we have described a new species of *Anaplasma*, *A. sparouinense*, in a gold miner by looking for tick-borne diseases in forest workers [38]. The high morbidity to these pathogens, as well as other health disorder (STIs, malnutrition... among the marginalized population of gold miners is evidence of a health inequity in this European territory of the Amazon (6). It also raises a public health concern because of the potential impact on the general population of French Guiana but also of the Guiana Shield because of the high mobility of gold miners. In the era of Global Health, special attention must be paid to these vulnerable populations in direct contact with the tropical ecosystem far from the care system and therefore under the radar of the usual surveillance system.

Supporting information

S1 Circuit. Circuit and pre-analytical conditioning of blood samples.

(DOCX)

S1 Dataset. Anonymized data set.

(XLSX)

Acknowledgments

The authors thank the Centre de Ressources Biologiques Amazonie (Biobank Amazonie), Cerba lab, and the team who collected data on the field: Mylène Cébé, Alan Ribeiro and Florine Corlin. The authors also thank the technicians of the National Reference Center for Leptospirosis (Institut Pasteur) for the serological analysis of serum samples.
Author Contributions

Conceptualization: Maylis Douine, Timothée Bonifay, Yann Lambert, Pascale Bourhy, Mathieu Picardeau, Mona Saout, Magalie Demar, Alice Sanna, Emilie Mosnier, Mathieu Nacher, Antoine Adenis, Martha Suarez-Mutis, Stephen Vreden, Loïc Epelboin, Roxane Schaub.

Data curation: Maylis Douine, Yann Lambert.

Formal analysis: Maylis Douine, Mathieu Nacher, Roxane Schaub.

Funding acquisition: Maylis Douine.

Investigation: Maylis Douine, Louise Mutricy, Audrey Godin, Martha Suarez-Mutis.

Methodology: Maylis Douine, Timothée Bonifay, Louise Mutricy, Muriel Suzanne Galindo, Pascale Bourhy, Mathieu Picardeau, Mona Saout, Romain Blaizot, Pierre Couppié, Mathieu Nacher, Antoine Adenis, Martha Suarez-Mutis, Stephen Vreden, Loïc Epelboin.

Project administration: Maylis Douine, Louise Mutricy, Muriel Suzanne Galindo, Antoine Adenis, Martha Suarez-Mutis, Stephen Vreden.

Resources: Maylis Douine, Muriel Suzanne Galindo, Pascale Bourhy, Mathieu Picardeau, Mona Saout, Magalie Demar, Loïc Epelboin.

Supervision: Maylis Douine, Martha Suarez-Mutis.

Validation: Timothée Bonifay, Yann Lambert, Alice Sanna, Roxane Schaub.

Visualization: Maylis Douine.

Writing – original draft: Maylis Douine.

Writing – review & editing: Timothée Bonifay, Yann Lambert, Louise Mutricy, Muriel Suzanne Galindo, Antoine Adenis, Martha Suarez-Mutis, Stephen Vreden.

References

1. Morens DM, Folkers GK, Fauci AS. The challenge of emerging and re-emerging infectious diseases. Nature. 2004 Jul 8; 430(6996):242–9. https://doi.org/10.1038/nature02759 PMID: 15241422

2. Jones KE, Patel NG, Levy MA, Storeygard A, Balk D, Gittleman JL, et al. Global trends in emerging infectious diseases. Nature. 2008; 451(7181):990–3. https://doi.org/10.1038/nature06536 PMID: 18288193

3. Dufour B. Les causes de l’émergence des maladies infectieuses. Bull Académie Natl Médecine. 2017 Sep; 2017(7–9):1189–95.

4. de Thoisy B, Duron O, Epelboin L, Musset L, Quénel P, Roche B, et al. Ecology, evolution, and epidemiology of zoonotic and vector-borne infectious diseases in French Guiana: Transdisciplinarity does matter to tackle new emerging threats. Infect Genet Evol. 2021;104:916. https://doi.org/10.1016/j.meegid.2021.104916 PMID: 34004361

5. Douine M, Lambert Y, Musset L, Hiwat H, Blume LR, Marchesini P, et al. Malaria in gold miners in the Guianas and the Amazon: current knowledge and challenges. Curr Trop Med Rep [Internet]. 2020 [cited 2020 Apr 30]; Available from: https://doi.org/10.1007/s40475-020-00202-5.

6. Douine M, Mosnier E, Le Hingrat Q, Charpentier C, Corlin F, Hureau L, et al. Illegal gold miners in French Guiana: a neglected population with poor health. BMC Public Health [Internet]. 2017; 18(1). Available from: http://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-017-4557-4. https://doi.org/10.1186/s12889-017-4557-4 PMID: 28716015

7. Douine M, Musset L, Corlin F, Pelleau S, Pasquier J, Mutricy L, et al. Prevalence of Plasmodium spp. in illegal gold miners in French Guiana in 2015: a hidden but critical malaria reservoir. Malar J. 2016; 15:315. https://doi.org/10.1186/s12936-016-1367-6 PMID: 27277831
8. Douine M, Lambert Y, Suzanne Galindo M, Mutricy L, Sanna A, Peterka C, et al. Self-diagnosis and self-treatment of malaria in hard-to-reach and mobile populations of the Amazon: results of Malakit, an international multicentric intervention research project. Lancet Reg Health—Am. 2021;

9. Le Tourneau FM. Chercheurs d’or—L’orpaillage clandestin en Guyane française [Internet]. CNRS Editions. 2020 [cited 2020 Sep 28]. 426 p. Available from: https://livre.fnac.com/a14373370/FRANCOIS-MICHEL-LE-TOURENAU-Chercheurs-d-or-L-orpaillage-clandestin-en-Guyane-francaise.

10. Vieira AS, Pinto PS, Lilenbaum W. A systematic review of leptospirosis on wild animals in Latin America. Trop Anim Health Prod. 2018 Feb; 50(2):229–38. https://doi.org/10.1007/s11250-017-1429-y PMID: 28967042

11. Petrakovsky J, Bianchi A, Fisun H, Nájera-Aguilar P, Pereira MM. Animal Leptospirosis in Latin America

12. Shearer FM, Moyes CL, Pigott DM, Brady OJ, Marinho F, Deshpande A, et al. Global yellow fever vaccination coverage from 1970 to 2016: an adjusted retrospective analysis. Lancet Infect Dis. 2017 Nov 1; 17(11):10770–89. https://doi.org/10.1016/S1473-3099(17)30419-X PMID: 28822780

13. Pan American Health Organization. Epidemiological update—Yellow Fever. Pan American Health; 2021 Dec.

14. Giovanetti M, de Mendonça MCL, Fonseca V, Mares-Guia MA, Fabri A, Xavier J, et al. Yellow Fever Virus Reemergence and Spread in Southeast Brazil, 2016–2019. J Virol. 2020 Dec 12; 94(1).

15. Flamand C, Bailly S, Fritzell C, Fernandes Pellerin S, Toure A, Chateau N, et al. Vaccination coverage in the context of the emerging Yellow Fever threat in French Guiana. PLoS Negl Trop Dis. 2019; 13(8): e0007661. https://doi.org/10.1371/journal.pntd.0007661 PMID: 31425507

16. Sanna A, Andrieu A, Carvalho L, Mayence C, Tabard P, Hachouf M, et al. Yellow fever cases in French Guiana, evidence of an active circulation in the Guiana Shield, 2017 and 2018. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull. 2018 Sep; 23(36). https://doi.org/10.2807/1560-7917.ES.2018.23.36.1800471 PMID: 30205871

17. Amanu N, Slifka MK. Questions regarding the safety and duration of immunity following live yellow fever vaccination. Expert Rev Vaccines. 2016; 15(12):1519–33. https://doi.org/10.1080/14760584.2016.1198259 PMID: 27267203

18. Epelboin L, Eldin C, Thill P, de Santi VM, Aboud P, Walter G, et al. Human O Fever on the Guiana Shield and Brazil: Recent Findings and Remaining Questions. Curr Trop Med Rep. 2021 Sep 1; 8(3):173–82. https://doi.org/10.1007/s40475-021-00243-4 PMID: 34094813

19. Epelboin L, Chesnais C, Bouillé C, Drogoù AS, Raoult D, Djossou F, et al. Q fever pneumonia in French Guiana: prevalence, risk factors, and prognostic score. Clin Infect Dis Off Publ Infect Dis Soc Am. 2012; 55(1):67–74.

20. Pommier de Santi V, Briolant S, Mahamat A, Ilcinkas C, Blanchet D, de Thoisy B, et al. Q fever epidemic in Cayenne, French Guiana, epidemiologically linked to three-toed sloth. Comp Immunol Microbiol Infect Dis. 2018 Feb; 56:34–8. https://doi.org/10.1016/j.cimid.2017.12.004 PMID: 29406281

21. Lamas CC, Rozental T, Bóa MN, Favacho ARM, Kirsten AH, da Silva APM, et al. Seroprevalence of Coxiella burnetii antibodies in human immunodeficiency virus-positive patients in Jacarépequã, Rio de Janeiro, Brazil. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2009 Dec;15 Suppl 2:140–1. https://doi.org/10.10111/j.1469-0691.2008.02144.x PMID: 19298403

22. Rozental T, Silva ASV da, Oliveira RC de, Favacho AR de M, Oliveira M de LA, Bastos Fi, et al. Seroprevalence of Bartonella spp., Coxiella burnetii, and Hantavirus among people who inject drugs in Rio de Janeiro, Brazil: a retrospective assessment of a biobank. Rev Inst Med Trop Sao Paulo. 2018; 60; e31. https://doi.org/10.1590/S1678-99462018600031 PMID: 30043935

23. Dreyfus A, Benschop J, Collins-Emerson J, Wilson P, Baker MG, Heuer C. Sero-prevalence and risk factors for leptospirosis in abattoir workers in New Zealand. Int J Environ Res Public Health. 2014 Feb 5; 11(2):1756–75. https://doi.org/10.3390/ijerph11021756 PMID: 24503973

24. Ambekar AN, Bharadwaj RS, Joshi SA, Kagal AS, Bal AM. Sero surveillance of leptospirosis among sewer workers in Pune. Indian J Public Health. 2004 Mar; 48(1):27–9. PMID: 15704723

25. F L M, Dm de A, Â C. [Sero prevalence of leptospirosis and associated factors in workers of the urban cleaning service of the Municipality of Asuncion, Paraguay]. Rev Chil Infectologia Organo Of Soc Chil Infectologia [Internet]. 2015 Dec [cited 2022 Jan 4];32(6). Available from: https://pubmed.ncbi.nlm.nih.gov/26928498/

26. Costa F, Hagan JE, Calcagno J, Kane M, Torgerson P, Martinez-Silveira MS, et al. Global Morbidity and Mortality of Leptospirosis: A Systematic Review. Small PLC, editor. PLoS Negl Trop Dis. 2015; 9 (9):e0003898. https://doi.org/10.1371/journal.pntd.0003898 PMID: 26379143
27. Epelboin L, Bourhy P, Le Turnier P, Schaub R, Mosnier E, Berlioz-Arthaud A, et al. La leptospirose en Guyane française et sur le bouclier des Guyanes. État des connaissances en 2016. Bull Société Pathol Exot. 2017 Aug; 110(3):165–79.

28. Turnier PL, Mosnier E, Schaub R, Bourhy P, Jolivet A, Crozet C, et al. Epidemiology of Human Leptospirosis in French Guiana (2007–2014): A Retrospective Study. Am J Trop Med Hyg. 2018 Jul 23; 99(3):590–6. https://doi.org/10.4269/ajtmh.17-0734 PMID: 30039781

29. Galan DI, Roess AA, Pereira SVC, Schneider MC. Epidemiology of human leptospirosis in urban and rural areas of Brazil, 2000–2015. PloS One. 2021; 16(3):e0247763. https://doi.org/10.1371/journal.pone.0247763 PMID: 33661947

30. Haute Autorité de santé. Diagnostic biologique de la leptospirose. rapport d'évaluation technologique. Haute Autorité de Santé; 2011.

31. Casanovas-Massana A, Pedra GG, Wunder EA, Diggle PJ, Begon M, Ko AI. Quantification of Leptospira interrogans Survival in Soil and Water Microcosms. Appl Environ Microbiol. 2018; 84(13):e00507–18. https://doi.org/10.1128/AEM.00507-18 PMID: 29703737

32. Douine M, Lazrek Y, Blanchet D, Pelleau S, Chanlin R, Corlin F, et al. Predictors of antimalarial self-medication in illegal gold miners in French Guiana: a pathway towards artemisinin resistance. J Antimicrob Chemother. 2018; 73(1):231–9. https://doi.org/10.1093/jac/dkx343 PMID: 29045645

33. Aucouturier AL. Parcours de soin des orpailleurs illégaux en Guyane française. Du premier symptôme à la consultation médicale au centre de santé de Maripasoula. [Cayenne]: Université de la Guyane; 2018.

34. Malmontet T, Guarmit B, Gaillet M, Michaud C, Garceran N, Chanlin R, et al. Spectrum of skin diseases in Amerindian villages of the Upper Oyapock, French Guiana. Int J Dermatol. 2020 May; 59(5):599–605. https://doi.org/10.1111/ijd.14848 PMID: 32227343

35. Loiseau R, Nabet C, Simon S, Ginouves M, Brousse P, Blanchet D, et al. American cutaneous leishmaniasis in French Guiana: an epidemiological update and study of environmental risk factors. Int J Dermatol. 2019; 58(11):1323–8. https://doi.org/10.1111/ijd.14625 PMID: 31524286

36. Rotureau B, Joubert M, Clyti E, Djossou F, Carme B. Leishmaniasis among Gold Miners, French Guiana. Emerg Infect Dis. 2006 Jul; 12(7):1169–70. https://doi.org/10.3201/eid1207.051466 PMID: 16848045

37. Simon S, Nacher M, Carme B, Basurko C, Roger A, Adenis A, et al. Cutaneous leishmaniasis in French Guiana: revising epidemiology with PCR-RFLP. Trop Med Health. 2017; 45:5. https://doi.org/10.1186/s41182-017-0045-x PMID: 28265182

38. Duron O, Koulal R, Musset L, Buysse M, Lambert Y, Jaulhac B, et al. A case of novel chronic anaplasmosis in splenectomized patient in Amazon rainforest. Emerg Infect Dis. 2022: 28(8): 1673–1676. https://doi.org/10.3201/eid2808.212425